Vector Biomed

What Vector Biomed does

Vector BioMed is a specialized Contract Vector Development and Manufacturing Organization (CVDMO) focused exclusively on lentiviral vectors for cell and gene therapy developers. Founded in January 2023 as a public benefit corporation spun out of the nonprofit Caring Cross, the company is headquartered in Gaithersburg, Maryland, and operates with a small team (~10–20 senior staff) led by executives with decades of lentiviral vector experience, including the team behind the vector used in Kymriah, the first FDA-approved gene therapy.

The company's core offering is the LENTIVERSE platform, organized into two commercial paths: VectorCraft for custom algorithm-optimized lentiviral vector design and GMP manufacturing, and LaunchSuite for ready-to-deploy, royalty-free CGMP vectors targeting anti-CD19 and anti-BCMA CAR-T programs. Manufacturing uses a proprietary serum-free, chemically defined suspension cell culture process that produces high-titer (>10⁹ TU/mL) clinical-grade vectors, with a single 1L batch yielding up to ~1,000 patient doses. Supporting services include preclinical vector production, commercial CGMP manufacturing, assay development, regulatory support, and cell manufacturing facility assistance. A specialized T-cell enrichment reagent, T-isopure, complements the platform for point-of-care CAR-T manufacturing.

Vector BioMed generates revenue through professional services and product sales on a quote-based B2B model with multi-year contracts, claiming up to 50% lower CGMP vector costs versus market average. The company serves three primary customer segments: (1) cell and gene therapy developers in the US and globally, (2) CIRM-funded California investigators through a preferred partnership, and (3) hospital systems and health ministries in low- and middle-income countries (India, Brazil, Turkey) pursuing decentralized CAR-T manufacturing via technology transfer partnerships coordinated through Caring Cross. Pricing is quote-based and not publicly disclosed; the public benefit corporation structure reserves capacity for global access at discounted terms.

Name

Vector Biomed

Legal name

Vector BioMed

Website

https://vectorbiomed.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Vector BioMed is a specialized lentiviral vector design and GMP manufacturing organization (CVDMO) serving cell and gene therapy developers, academic researchers, and global health partners in LMICs through its LENTIVERSE platform offering custom (VectorCraft) and ready-to-deploy (LaunchSuite) lentiviral vector solutions.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Lentiviral vector manufacturing
• Contract vector development
• Cell and gene therapy CDMO
• CAR-T vector solutions
• GMP viral vector production

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Lentiviral Vector CDMO Services: Vector BioMed operates as a Contract Vector Development and Manufacturing Organization (CVDMO), providing custom and ready-to-deploy lentiviral vectors to biotech developers, research institutions, and global health partners. Revenue is generated through service fees for vector design, optimization, pre-clinical manufacturing, GMP manufacturing, and regulatory support. The company offers both bespoke VectorCraft solutions and standardized LaunchSuite products, serving clients from early-stage development through commercialization.
2. LENTIVERSE™ Platform Products: LaunchSuite provides ready-to-deploy CGMP vectors for anti-CD19 and anti-BCMA CAR-T targets, sold as complete kits including documentation and process workflows. VectorCraft offers custom vector development services. Both are priced with transparent economics and no hidden royalty fees, with costs up to 50% below market average for CGMP vectors.
3. Regulatory and Assay Development Services: Custom assay development, regulatory strategy and submission support, process characterization and validation to prepare therapies for BLA submission and commercial launch. These professional services are offered as part of the end-to-end development offering.
4. Global Access / Nonprofit Pricing: As a public benefit corporation, Vector BioMed reserves a percentage of manufacturing capacity and special pricing to serve lower-income countries, aligned with parent nonprofit Caring Cross's mission. This includes discounted vector supply and technology transfer to global health partners in LMICs.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Vector BioMed is a Contract Vector Development and Manufacturing Organization (CVDMO) that designs, optimizes, and GMP-manufactures high-titer lentiviral vectors for cell and gene therapy developers. Its LENTIVERSE™ platform delivers both custom vector development (VectorCraft™) and ready-to-deploy CAR-T vector kits (LaunchSuite™) for targets such as anti-CD19 and anti-BCMA, using a serum-free, chemically defined suspension manufacturing process that produces clinical-grade vectors exceeding 10⁹ TU/mL.

Product overview

Vector BioMed is a purpose-driven Contract Vector Development and Manufacturing Organization (CVDMO) that operates as a unified platform-plus-modules architecture. The core LENTIVERSE™ platform is organized into two main pathways: VectorCraft (custom lentiviral vector development and manufacturing) and LaunchSuite (ready-to-deploy CAR-T solutions). These are supported by a full suite of services including GMP manufacturing, preclinical production, assay development, regulatory support, and cell manufacturing facility support. The company also provides T-isopure™ as a specialized reagent for simplified T cell enrichment. Unlike broad-spectrum CDMOs, Vector BioMed delivers specialized expertise focused solely on lentiviral vectors, with reproducible quality and accelerated timelines from early-stage development through commercial-scale manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• LENTIVERSE™: A comprehensive lentiviral vector platform offering both custom VectorCraft solutions and rapid LaunchSuite formats for CAR-T manufacturing and custom vector design.
• VectorCraft
• LaunchSuite
• T-isopure™

Products and services

• LENTIVERSE™ Platform Modular lentiviral vector development and manufacturing ecosystem combining custom VectorCraft services and LaunchSuite ready-to-deploy CAR-T solutions for biotech developers, research institutions, and global health partners.
• VectorCraft™ Platform-based custom lentivirus development and manufacturing service delivering algorithm-optimized vectors with high functional titers and an IND-ready solution with transparent economics, no hidden licensing fees or royalties, and up to 50% reduction in CGMP costs versus market average.
• LaunchSuite™ Complete ready-to-deploy solution for generic CAR-T manufacturing providing royalty-free, fully characterized CGMP lentiviral vectors for anti-CD19 and anti-BCMA targets, with documentation and decentralized cell manufacturing workflows enabling point-of-care production.
• GMP Lentiviral Vector Manufacturing CGMP manufacturing services producing high-titer (>10⁹ TU/mL), clinical-grade lentiviral vectors using a scalable, chemically defined, serum-free suspension process to support regulatory approval and commercialization.
• Preclinical Lentiviral Vector Production Fast, reliable production of preclinical vectors to support in vitro and in vivo studies, ensuring smooth transition to CGMP manufacturing.
• Commercial Vector Production Commercial-grade CGMP vector manufacturing and ongoing support to seamlessly transition products from clinical development to full commercialization.
• Assay Development Custom assay development services to test parameters specific to vector or CAR-T cell product.
• Regulatory Support Regulatory support for clinical development and commercialization including regulatory meetings, submissions, and BLA strategy.
• Cell Manufacturing Facility Support Expert support for CGMP CAR-T cell manufacturing within both existing cleanroom infrastructures and modular cleanroom facilities to ensure operational readiness and compliance.
• T-isopure™ Simplified, cost-effective solution for T cell enrichment using negative selection for CAR-T production, reducing process complexity while maintaining integrity and performance needed for clinical use.

Quantifiable outcome

• Up to 50% reduction in CGMP vector manufacturing costs compared to average market costs
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Cartogene Therapeutics Pvt Ltd.minorOEM/ Whitelabel/ Licensing Partner · 30 March 2026Cartogene Therapeutics in-licensed CGT-19, a CD19 CAR T construct from Vector Biomed Inc., as a strategy to expand CAR-T therapy accessibility in certain countries. Demonstrates Vector BioMed's IP licensing business model for proprietary CAR constructs beyond core vector manufacturing.
• Muni Seva Ashram / Kailash Cancer Hospital and Research Center (KCHRC)coreStrategic or Co-development Partner · 24 June 2025Strategic partnership making Vector BioMed the preferred and exclusive CVDMO partner for KCHRC's cell therapy program. KCHRC is a 400-bed nonprofit hospital in rural Gujarat, India serving 70,000+ outpatients annually. First patients expected to receive CAR-T therapy in Q1 2026. Vector BioMed supplies LENTIVERSE-based vectors and validated CAR-T processes including anti-CD19 CAR-T solution. The 1,800-sq-ft GMP facility was built on-site. This is the first CAR-T program in Gujarat and among the first in India outside major metros.
• California Institute for Regenerative Medicine (CIRM)coreStrategic or Co-development Partner · 2 August 2023Preferred lentiviral vector manufacturing partner within CIRM's Industry Alliance Program. CIRM has $5.5B in funding and over 150 active stem cell programs. Vector BioMed assists CIRM investigators in accelerating their development to the clinic by leveraging the VBM team's extensive experience in design and manufacture of pre-clinical and GMP-grade lentiviral vectors. CIRM-funded researchers in California receive preferential access to Vector BioMed's services.
• Caring CrosscoreStrategic or Co-development PartnerVector BioMed was the first company spun out from Caring Cross, a 501(c)(3) nonprofit dedicated to accelerating advanced medicines and enabling access to cures for all patients. Caring Cross leads international technology transfer programs (Brazil's Fiocruz, Turkey's KOQ Healthcare) and global access initiatives that leverage Vector BioMed's manufacturing platform. Vector BioMed reserves manufacturing capacity for lower-income countries per Caring Cross's mission.
• Koç Healthcare / KOQ Healthcare (Turkey)minorStrategic or Co-development PartnerPartnership through Caring Cross to bring point-of-care CAR-T manufacturing to Turkey. Vector BioMed provides the scalable vector manufacturing platform supporting localized therapy production at Koç Healthcare facilities. Aligned with Caring Cross's global access mission to empower regional healthcare systems to manufacture advanced therapies sustainably.
• Fiocruz / Instituto Nacional de Câncer (INCA) — BrazilminorStrategic or Co-development PartnerCaring Cross-led technology transfer initiative with Brazil's Fiocruz (Fundação Oswaldo Cruz) and INCA, backed by the Brazilian Ministry of Health. Full technology transfer for CAR-T and lentiviral vector manufacturing enables Brazil to produce therapies locally at approximately $35,000 per dose (vs. $400,000+ in high-income countries). Fiocruz acts as a manufacturing hub and reference facility for Latin America. Vector BioMed supports this initiative through its parent Caring Cross.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Oxford BioMedica: UK-based pure-play lentiviral vector CDMO and the most established specialist in the category. Directly comparable to Vector BioMed as a focused lentiviral vector development and GMP manufacturing services provider, with similar dual-offering (custom + platform products) and a comparable gene therapy client base.
• AGC Biologics: CDMO with dedicated viral vector (lentiviral and AAV) and cell therapy manufacturing capabilities, serving similar biotech clients. Comparable in scale and focus to Vector BioMed, with multi-site GMP capacity.
• Yposkesi: French CDMO specialized in viral vector (lentiviral and AAV) GMP manufacturing for gene and cell therapy developers. Closely comparable niche specialist serving European biotech clients, with similar scale and service offering.
• Cobra Biologics (Cognate BioServices): Viral vector and plasmid DNA CDMO (now part of the Cognate BioServices family), offering lentiviral and AAV GMP manufacturing. Directly comparable specialist competing for gene therapy outsourcing contracts.

Broad incumbents

• Miltenyi Biotec: Acquired Lentigen Technology — Vector BioMed's own heritage platform — making Miltenyi the largest and most directly comparable competitor. Offers cell and gene therapy manufacturing, lentiviral/AAV vectors, and T-cell processing reagents, with vastly greater scale, multi-site capacity, and balance sheet.
• Lonza Cell & Gene Technologies: One of the largest global CDMOs with a dedicated Cell & Gene Technologies business covering viral vector manufacturing (AAV and lentiviral) and cell therapy services. Broad-spectrum incumbent competing for the same biotech outsourcing dollars Vector BioMed targets.
• Catalent (Paragon Bioservices): Major CDMO with significant viral vector and cell therapy manufacturing capacity acquired through Paragon Bioservices. Competes head-to-head with Vector BioMed on lentiviral vector GMP manufacturing for CAR-T and gene therapy developers.
• Charles River Laboratories: Provides viral vector CDMO services (lentiviral and AAV) through its Biologics Services / CDMO segment, serving gene and cell therapy developers globally. Established CDMO competing in the same viral vector outsourcing market.

Emerging players

• Genezen: US-based emerging viral vector CDMO focused on lentiviral and AAV GMP manufacturing for gene therapy developers. Comparable specialized offering at similar early-growth stage to Vector BioMed.
• bluebird bio: Gene therapy developer with deep lentiviral vector expertise and historically significant internal manufacturing capability. Comparable from a technology platform standpoint and represents both a potential Vector BioMed client and a competitor for lentiviral-based programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vectorbiomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vector Biomed